Drug Information

Drug General Information
Drug ID
D05FKE
Former ID
DNC010254
Drug Name
6-(piperazin-1-yl)-9-propyl-9H-purine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530516]
Formula
C12H18N6
Canonical SMILES
CCCN1C=NC2=C1N=CN=C2N3CCNCC3
InChI
1S/C12H18N6/c1-2-5-18-9-16-10-11(14-8-15-12(10)18)17-6-3-13-4-7-17/h8-9,13H,2-7H2,1H3
InChIKey
BWJIAIMMFVYUQA-UHFFFAOYSA-N
PubChem Compound ID
46228441
Target and Pathway
Target(s) 5-hydroxytryptamine 2C receptor Target Info Inhibitor [530516]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channels
PANTHER Pathway 5HT2 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (q) signalling events
WikiPathways Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.